

IN THE CLAIMS

1. (canceled)

2. (currently amended) A method of screening for therapeutic agents useful in the treatment of a cardiovascular disease ~~selected from cardiovascular diseases, CNS disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases~~ in a mammal comprising the steps of

i) determining the activity of a formyl peptide receptor-like 2 (FPRL2) ~~FPRL2~~ polypeptide ~~at a certain concentration of a test compound or~~ in the absence of a ~~said~~ test compound,

ii) determining the activity of said polypeptide in the presence of the ~~at a different concentration of said~~ test compound; and

iii) identifying the test compound as a potential therapeutic agent for the treatment of cardiovascular disease if the activity of the FPRL2 polypeptide in the presence of the test compound is different than the activity of the FPRL2 polypeptide in the absence of the test compound.

3-26. (canceled)

27. (previously presented) The method of claim 26, wherein the cell is *in vitro*.

28. (previously presented) The method of claim 2, wherein the FPRL2 polypeptide is in a cell-free system.

29-31. (canceled)

32. (new) The method of claim 2, wherein the FPRL2 polypeptide is in a cell.